Experts at last week's BIO meeting in Philadelphia discussed the long-term implications of many gene therapies hitting the market, and ways their prices could be lowered so they'd be more cost-effective.
While the U.K. biopharma industry will likely continue to play a significant role on the global stage, it could have trouble attracting talent, while European firms prepare for a worst-case scenario.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The industry should also not be shy about going after actors who increase prices on drugs without increasing value, said the chair, Jeremy Levin, who is CEO of Ovid Therapeutics.
At BIO Tuesday, panelists discussed the lack of racial, ethnic and gender diversity in clinical trials and its potential implications.
Some Chinese attendees said they are not yet affected but maybe while others said they weren't affected and that the trade impasse was likely to turn the attention of the biotech companies to Europe. Chinese pharma wouldn't be affected.